<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Akeso Inc — News on 6ix</title>
<link>https://6ix.com/company/akeso-inc</link>
<description>Latest news and press releases for Akeso Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 08:07:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/akeso-inc" rel="self" type="application/rss+xml" />
<item>
<title>Ivonescimab Receives Major Recommendations Across Multiple Therapies in the 2026 CSCO NSCLC Guideline</title>
<link>https://6ix.com/company/akeso-inc/news/ivonescimab-receives-major-recommendations-across-multiple-therapies-in-the-2026-csco-nsclc-guideline</link>
<guid isPermaLink="true">https://6ix.com/company/akeso-inc/news/ivonescimab-receives-major-recommendations-across-multiple-therapies-in-the-2026-csco-nsclc-guideline</guid>
<pubDate>Tue, 28 Apr 2026 08:07:00 GMT</pubDate>
<description>Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that ivonescimab, the company's first-in-class PD-1/VEGF bispecific antibody, has secured multiple authoritative updates and upgrades across first-line and later-line settings in the officially updated 2026 Chinese Society of Clinical Oncology (CSCO) Guideline for the Diagnosis and Treatment of Non-Small Cell Lung Cancer (NSCLC). These strong recommendations further solidify ivonescimab's breakthrough clinical value and its positio</description>
</item>
<item>
<title>Cadonilimab Combination Demonstrates Promising Survival Benefit in Locally Advanced Pancreatic Cancer: Phase II COMPASSION-26 Data Presented at AACR 2026</title>
<link>https://6ix.com/company/akeso-inc/news/cadonilimab-combination-demonstrates-promising-survival-benefit-in-locally-advanced-pancreatic-cancer-phase-ii-compassion-26-data-presented-at-aacr-2026</link>
<guid isPermaLink="true">https://6ix.com/company/akeso-inc/news/cadonilimab-combination-demonstrates-promising-survival-benefit-in-locally-advanced-pancreatic-cancer-phase-ii-compassion-26-data-presented-at-aacr-2026</guid>
<pubDate>Tue, 21 Apr 2026 02:54:00 GMT</pubDate>
<description>Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that positive Phase II results from the COMPASSION-26 study evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, in combination with chemotherapy as first-line treatment for advanced pancreatic ductal adenocarcinoma (PDAC), were presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting.</description>
</item>
<item>
<title>Akeso Presents Updated Data on Cadonilimab Combination Therapy in PD-(L)1 Inhibitor-Resistant Advanced NSCLC at ELCC 2026</title>
<link>https://6ix.com/company/akeso-inc/news/akeso-presents-updated-data-on-cadonilimab-combination-therapy-in-pd-l1-inhibitor-resistant-advanced-nsclc-at-elcc-2026</link>
<guid isPermaLink="true">https://6ix.com/company/akeso-inc/news/akeso-presents-updated-data-on-cadonilimab-combination-therapy-in-pd-l1-inhibitor-resistant-advanced-nsclc-at-elcc-2026</guid>
<pubDate>Tue, 07 Apr 2026 03:28:00 GMT</pubDate>
<description>Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that, at the 2026 European Lung Cancer Congress (ELCC 2026), it reported updated results with a median follow-up of 21.45 months from a prospective, open-label, single-arm, multicenter Phase Ib/II study evaluating cadonilimab in combination with anlotinib and docetaxel in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who progressed after prior PD-(L)1 inhibitor-based therapy.</description>
</item>
<item>
<title>Ivonescimab Shows Quality of Life Benefits in Chemotherapy-Free First-Line NSCLC: Health-Related Quality of Life Data from the HARMONi-2 Study Presented at ELCC 2026</title>
<link>https://6ix.com/company/akeso-inc/news/ivonescimab-shows-quality-of-life-benefits-in-chemotherapy-free-first-line-nsclc-health-related-quality-of-life-data-from-the-harmoni-2-study-presented-at-elcc-2026</link>
<guid isPermaLink="true">https://6ix.com/company/akeso-inc/news/ivonescimab-shows-quality-of-life-benefits-in-chemotherapy-free-first-line-nsclc-health-related-quality-of-life-data-from-the-harmoni-2-study-presented-at-elcc-2026</guid>
<pubDate>Tue, 31 Mar 2026 09:40:00 GMT</pubDate>
<description>Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the results of health-related quality of life (HRQoL) data (Poster: 107P) from the HARMONi-2 study at the 2026 European Lung Cancer Congress (ELCC). The study evaluated ivonescimab, the company's first-in-class PD-1/VEGF bispecific antibody, versus pembrolizumab as a first-line treatment for patients with PD-L1–positive non-small cell lung cancer (NSCLC).</description>
</item>
<item>
<title>Akeso Reports Full-Year 2025 Financial Results</title>
<link>https://6ix.com/company/akeso-inc/news/akeso-reports-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/akeso-inc/news/akeso-reports-full-year-2025-financial-results</guid>
<pubDate>Fri, 27 Mar 2026 03:54:00 GMT</pubDate>
<description>Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced its 2025 annual results, highlighting a year of comprehensive, strategic leaps across all facets of its business.</description>
</item>
<item>
<title>Akeso Advances "IO 2.0 + ADC 2.0" Strategy with Phase II Initiation of Novel ADCs Combined with Ivonescimab and Cadonilimab</title>
<link>https://6ix.com/company/akeso-inc/news/akeso-advances-io-20-adc-20-strategy-with-phase-ii-initiation-of-novel-adcs-combined-with-ivonescimab-and-cadonilimab</link>
<guid isPermaLink="true">https://6ix.com/company/akeso-inc/news/akeso-advances-io-20-adc-20-strategy-with-phase-ii-initiation-of-novel-adcs-combined-with-ivonescimab-and-cadonilimab</guid>
<pubDate>Wed, 25 Mar 2026 02:40:00 GMT</pubDate>
<description>Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that it has received clearance from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) to initiate Phase II clinical trials for AK146D1, a first-in-class Trop2 /Nectin4 bispecific antibody-drug conjugate (ADC), and AK138D1, an innovative HER3-targeting ADC.</description>
</item>
<item>
<title>Akeso Announces Global First-in-Class Trispecific Antibody AK150 Enters Clinical Trials: A Triple-Target Approach to Overcome Immunotherapy Resistance</title>
<link>https://6ix.com/company/akeso-inc/news/akeso-announces-global-first-in-class-trispecific-antibody-ak150-enters-clinical-trials-a-triple-target-approach-to-overcome-immunotherapy-resistance</link>
<guid isPermaLink="true">https://6ix.com/company/akeso-inc/news/akeso-announces-global-first-in-class-trispecific-antibody-ak150-enters-clinical-trials-a-triple-target-approach-to-overcome-immunotherapy-resistance</guid>
<pubDate>Mon, 16 Mar 2026 02:05:00 GMT</pubDate>
<description>Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced today that its proprietary first-in-class trispecific antibody, AK150 (ILT2/ILT4/CSF1R), has received Investigational New Drug (IND) clearance from the National Medical Products Administration (NMPA) for clinical trials in patients with advanced solid tumors.</description>
</item>
<item>
<title>Cadonilimab Achieves 100% 24-Month OS in Complete Responders in R/M Cervical Cancer Based on Long-Term Phase II Results</title>
<link>https://6ix.com/company/akeso-inc/news/cadonilimab-achieves-100percent-24-month-os-in-complete-responders-in-rm-cervical-cancer-based-on-long-term-phase-ii-results</link>
<guid isPermaLink="true">https://6ix.com/company/akeso-inc/news/cadonilimab-achieves-100percent-24-month-os-in-complete-responders-in-rm-cervical-cancer-based-on-long-term-phase-ii-results</guid>
<pubDate>Thu, 05 Mar 2026 02:26:00 GMT</pubDate>
<description>Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the latest long-term survival analysis data from the China pivotal registrational Phase II study (COMPASSION-03/AK104-201) of cadonilimab as a monotherapy for patients with recurrent or metastatic cervical cancer (R/M CC) who have failed prior platinum-containing chemotherapy, were presented in a late-breaking oral presentation by Professor Wu Xiaohua from Fudan University Shanghai Cancer Center, the Principal Investigator, at the 2</description>
</item>
<item>
<title>Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)</title>
<link>https://6ix.com/company/akeso-inc/news/akeso-and-inovio-announce-clinical-collaboration-to-advance-novel-combination-therapy-for-glioblastoma-gbm</link>
<guid isPermaLink="true">https://6ix.com/company/akeso-inc/news/akeso-and-inovio-announce-clinical-collaboration-to-advance-novel-combination-therapy-for-glioblastoma-gbm</guid>
<pubDate>Wed, 04 Mar 2026 13:52:00 GMT</pubDate>
<description>Akeso, Inc. (9926.HK) ("Akeso"), and INOVIO (NASDAQ: INO) today announced that they have entered into a clinical trial collaboration and supply agreement to evaluate cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, in combination with INO-5412, INOVIO's DNA immunotherapy candidate, for the potential treatment of GBM. The combination therapy will be studied as a part of INSIGhT, the innovative Phase II adaptive platform trial sponsored by the Dana-Farber Cancer Institute and c</description>
</item>
<item>
<title>INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)</title>
<link>https://6ix.com/company/akeso-inc/news/inovio-and-akeso-announce-clinical-collaboration-to-advance-novel-combination-therapy-for-glioblastoma-gbm-22</link>
<guid isPermaLink="true">https://6ix.com/company/akeso-inc/news/inovio-and-akeso-announce-clinical-collaboration-to-advance-novel-combination-therapy-for-glioblastoma-gbm-22</guid>
<pubDate>Wed, 04 Mar 2026 13:05:00 GMT</pubDate>
<description>INOVIO (NASDAQ: INO), and Akeso, Inc. (9926.HK) ("Akeso") today announced that they have entered into a clinical trial collaboration and supply agreement to evaluate INO-5412, INOVIO's DNA immunotherapy candidate, in combination with cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, for the potential treatment of GBM. The combination therapy will be studied as a part of INSIGhT, the innovative Phase 2 adaptive platform trial sponsored by the Dana-Farber Cancer Institute and co</description>
</item>
<item>
<title>Akeso's IL-4Rα/ST2 Bispecific Antibody Cleared for Seven Phase II Studies in China Spanning Respiratory and Autoimmune Indications</title>
<link>https://6ix.com/company/akeso-inc/news/akesos-il-4r-st2-bispecific-090100576</link>
<guid isPermaLink="true">https://6ix.com/company/akeso-inc/news/akesos-il-4r-st2-bispecific-090100576</guid>
<pubDate>Wed, 11 Feb 2026 09:01:00 GMT</pubDate>
<description>Akeso, Inc. (9926.HK) is pleased to announce that the National Medical Products Administration has approved the initiation of Phase II clinical trials for AK139, a first-in-class IL-4Rα/ST2-targeting bispecific antibody, across seven indications. These indications include chronic obstructive pulmonary disease (COPD), severe bronchial asthma, chronic spontaneous urticaria, allergic rhinitis, chronic rhinosinusitis with nasal polyps, moderate-to-severe atopic dermatitis, and prurigo nodularis. Wit</description>
</item>
<item>
<title>Akeso Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer</title>
<link>https://6ix.com/company/akeso-inc/news/akeso-receives-fifth-breakthrough-therapy-022600217</link>
<guid isPermaLink="true">https://6ix.com/company/akeso-inc/news/akeso-receives-fifth-breakthrough-therapy-022600217</guid>
<pubDate>Fri, 06 Feb 2026 02:26:00 GMT</pubDate>
<description>Akeso, Inc. (9926.HK) is pleased to announce that ivonescimab, its global first-in-class bispecific antibody targeting PD-1 and VEGF, has been granted its fifth Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). This latest designation applies to ivonescimab in combination with chemotherapy for the first-line treatment of advanced biliary tract cancer (BTC).</description>
</item>
<item>
<title>Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026"</title>
<link>https://6ix.com/company/akeso-inc/news/ivonescimab-included-firstword-pharmas-drugs-045100394</link>
<guid isPermaLink="true">https://6ix.com/company/akeso-inc/news/ivonescimab-included-firstword-pharmas-drugs-045100394</guid>
<pubDate>Thu, 29 Jan 2026 04:51:00 GMT</pubDate>
<description>Akeso, Inc. (9926.HK) is pleased to share that the international industry media FirstWord Pharma released its list titled "Spotlight On: The Drugs That Will Shape 2026", providing an in-depth analysis of 20 key drugs poised to define the trajectory of the global pharmaceutical industry and transform disease treatment paradigms in 2026 and beyond. Akeso/Summit Therapeutics' ivonescimab(PD-1/VEGF bispecific antibody) was selected for inclusion. It stands as the only drug on this list originating f</description>
</item>
<item>
<title>Akeso Announces NMPA Acceptance of Second NDA for Gumokimab (IL-17A Inhibitor) in Active Ankylosing Spondylitis</title>
<link>https://6ix.com/company/akeso-inc/news/akeso-announces-nmpa-acceptance-second-112400604</link>
<guid isPermaLink="true">https://6ix.com/company/akeso-inc/news/akeso-announces-nmpa-acceptance-second-112400604</guid>
<pubDate>Mon, 19 Jan 2026 11:24:00 GMT</pubDate>
<description>Akeso, Inc. (9926.HK) announced that its supplemental New Drug Application (sNDA) for gumokimab (AK111), a novel humanized anti-IL-17A monoclonal antibody for the treatment of active ankylosing spondylitis (AS), has been accepted for review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). There are approximately 4 million AS patients in China, and gumokimab represents a potentially promising new therapeutic option for this disease.</description>
</item>
<item>
<title>Head-to-Head Real-World Data: Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer</title>
<link>https://6ix.com/company/akeso-inc/news/head-to-head-real-world-data-cadonilimab-outperforms-pd-1-inhibitors-in-first-line-pd-l1-low-gastric-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/akeso-inc/news/head-to-head-real-world-data-cadonilimab-outperforms-pd-1-inhibitors-in-first-line-pd-l1-low-gastric-cancer</guid>
<pubDate>Wed, 14 Jan 2026 03:54:00 GMT</pubDate>
<description>Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), comparing cadonilimab plus chemotherapy against a PD-1 inhibitor plus chemotherapy for the first-line (1L) treatment for advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS <5 (a propensity-matched, retrospective cohort study).</description>
</item>
<item>
<title>Ivonescimab's Updated Label Shows Positive Dual Results in PFS and OS from HARMONi-A Study</title>
<link>https://6ix.com/company/akeso-inc/news/ivonescimabs-updated-label-shows-positive-025000628</link>
<guid isPermaLink="true">https://6ix.com/company/akeso-inc/news/ivonescimabs-updated-label-shows-positive-025000628</guid>
<pubDate>Wed, 07 Jan 2026 02:50:00 GMT</pubDate>
<description>Akeso, Inc. (9926.HK) announced that the National Medical Products Administration has approved a significant label update in China for its internally developed, first-in-class PD-1/VEGF bispecific antibody, ivonescimab. The updated label incorporates final analysis data from the AK112-301/HARMONi-A study, which demonstrated statistically significant and clinically meaningful dual benefits in both progression-free survival (PFS) and overall survival (OS) for ivonescimab combination therapy in pat</description>
</item>
<item>
<title>Cadonilimab (PD-1/CTLA-4) Receives FDA Clearance for Global Phase III First-Line Gastric Cancer Trial Versus Nivolumab</title>
<link>https://6ix.com/company/akeso-inc/news/cadonilimab-pd-1ctla-4-receives-fda-clearance-for-global-phase-iii-first-line-gastric-cancer-trial-versus-nivolumab</link>
<guid isPermaLink="true">https://6ix.com/company/akeso-inc/news/cadonilimab-pd-1ctla-4-receives-fda-clearance-for-global-phase-iii-first-line-gastric-cancer-trial-versus-nivolumab</guid>
<pubDate>Fri, 12 Dec 2025 02:31:00 GMT</pubDate>
<description>Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in gastric cancer evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody. The study will compare cadonilimab plus chemotherapy against chemotherapy with or without nivolumab as first-line treatment for HER2-negative, unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma.</description>
</item>
<item>
<title>Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented at ESMO IO 2025</title>
<link>https://6ix.com/company/akeso-inc/news/updated-efficacy-data-of-ivonescimab-combined-with-chemotherapy-as-first-line-treatment-for-tnbc-presented-at-esmo-io-2025</link>
<guid isPermaLink="true">https://6ix.com/company/akeso-inc/news/updated-efficacy-data-of-ivonescimab-combined-with-chemotherapy-as-first-line-treatment-for-tnbc-presented-at-esmo-io-2025</guid>
<pubDate>Thu, 11 Dec 2025 01:53:00 GMT</pubDate>
<description>Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the presentation of a Phase II clinical study that included a longer-term efficacy data evaluating ivonescimab (a PD-1/VEGF bispecific antibody) combined with chemotherapy as a first-line treatment for locally advanced unresectable or metastatic triple-negative breast cancer (TNBC) at the 2025 European Society for Medical Oncology Immuno-Oncology Congress (ESMO IO) in London, UK.</description>
</item>
<item>
<title>Phase II Data of Cadonilimab Regimen as Neoadjuvant Therapy for Resectable Gastric Cancer Presented at ESMO Asia 2025</title>
<link>https://6ix.com/company/akeso-inc/news/phase-ii-data-of-cadonilimab-regimen-as-neoadjuvant-therapy-for-resectable-gastric-cancer-presented-at-esmo-asia-2025</link>
<guid isPermaLink="true">https://6ix.com/company/akeso-inc/news/phase-ii-data-of-cadonilimab-regimen-as-neoadjuvant-therapy-for-resectable-gastric-cancer-presented-at-esmo-asia-2025</guid>
<pubDate>Tue, 09 Dec 2025 07:50:00 GMT</pubDate>
<description>Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that data from the Phase II study (COMPASSION-25) for its first-in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, in combination with SOX regimen (oxaliplatin + tegafur/gimeracil/oteracil) as neoadjuvant therapy for resectable gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, was presented at the 2025 ESMO Asia Congress.</description>
</item>
<item>
<title>Significant Improvement in Quality of Life Reported in Updated HARMONi-6 Data for Ivonescimab at ESMO Asia</title>
<link>https://6ix.com/company/akeso-inc/news/significant-improvement-in-quality-of-life-reported-in-updated-harmoni-6-data-for-ivonescimab-at-esmo-asia</link>
<guid isPermaLink="true">https://6ix.com/company/akeso-inc/news/significant-improvement-in-quality-of-life-reported-in-updated-harmoni-6-data-for-ivonescimab-at-esmo-asia</guid>
<pubDate>Tue, 09 Dec 2025 02:02:00 GMT</pubDate>
<description>Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that at the 2025 ESMO Asia Congress, updated results from the pivotal Phase III HARMONi-6 study (AK112-306) were shared in an oral presentation by Professor Shun Lu from Shanghai Chest Hospital. The study evaluates ivonescimab (a first-in-class PD-1/VEGF bispecific antibody) combined with chemotherapy versus tislelizumab combined with chemotherapy in first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC).</description>
</item>
</channel>
</rss>